logo-loader
Eden BioSolutions

US EPA registration for Mevalone Delta

RNS Number : 0048D
Eden Biosolutions PLC
13 November 2026
 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 


 

Eden BioSolutions plc

(“Eden” or “the Company”)

 

US EPA registration for Mevalone Delta

 

Eden BioSolutions plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technologies, announces that the United States Environmental Protection Agency ("EPA") has granted an unconditional registration under the Federal Insecticide, Fungicide, and Rodenticide Act ("FIFRA") for Mevalone Delta, an optimised biofungicide formulation based upon Eden’s registered active ingredients and microencapsulation technology, Sustaine® (EPA Reg. No. 92331-6).

 

  • Registration covers a variety of fungal diseases on a wide range of high-value crops
  • The crops covered by the approved label had a combined US farm-gate value of c. $33 billion in 2024
  • Total addressable market for Mevalone Delta in the US estimated to be in the region of $144 million
  • Significant opportunity to grow sales across North America

 

The registration

This registration covers the control of a range of fungal diseases on a broad list of high-value crops, including grapes (table, wine and raisin), almonds, strawberries, and other berries. Target diseases on the approved label include grey mould (Botrytis cinerea), powdery mildew, Sclerotinia (white mould), brown rot blossom blight (Monilinia) and chocolate spot (Botrytis fabae). This registration is required before a pesticide can be sold or distributed in the United States and Mevalone Delta will now undergo state-level review and registration, which is expected to take between one and twelve months, depending upon the state.

 

Mevalone Delta contains the same three naturally derived active ingredients as Mevalone® – eugenol, geraniol and thymol – and is classified by the Fungicide Resistance Action Committee ("FRAC") as a Group BM01 fungicide with multiple modes of action. It is therefore suitable for use in integrated pest management programmes and to delay or prevent the development of resistance to single-site fungicides. The label permits application up to three days before harvest, giving growers flexibility to protect crops late in the season. This optimised formulation allows us to position the product for a wider overall segment, competing in more cost sensitive segments whilst still delivering high levels of efficacy.

 

The US market opportunity

The United States is one of the world's largest markets for crop protection products, and the crops on the Mevalone Delta label are among the most valuable grown in the country. Based on USDA data, the crops covered by the approved label had a combined US farm-gate value of approximately $33 billion in 2024. This includes grapes (approximately $6.2 billion), almonds ($5.7 billion), leafy vegetables including lettuce, spinach and celery ($5.5 billion), and strawberries ($4.0 billion). Growers of these crops face increasing pressure from retailers, export markets and regulators to reduce chemical residues, supporting demand for effective biological alternatives.

 

The Company estimates the total addressable market for Mevalone Delta in the US to be in the region of $144 million, with an expectation of achieving a market share of around 3% at the point of peak sales.

 

Mevalone Delta will be distributed in the US by Sipcam Agro USA, Inc. ("Sipcam"), Eden's existing US commercial partner for Mevalone.

 

Sean Smith, Chief Executive Officer of Eden BioSolutions plc, commented: “The registration of Mevalone Delta is another significant milestone for Eden in the United States, one of the world’s largest markets for crop protection products. The breadth of the label, spanning a wide range of high-value crops worth more than $30 billion annually at the farm gate, gives Eden and our partner, Sipcam, a significant opportunity to grow sales across North America.

 

“Mevalone Delta offers growers an effective, residue-friendly disease control tool with multiple modes of action, which fits well in resistance management programmes and can be used almost up to harvest. As state registrations are secured over the coming months, we look forward to working with Sipcam to bring Mevalone Delta to growers and to providing further updates on its commercial progress.”

 

Brent Marek, Chief Executive Officer of Sipcam Agro USA, commented: “We are delighted to add Mevalone Delta to our portfolio, following its registration by the EPA. Growers of high-value fruit, vegetable and speciality crops continue to look for effective and sustainable biological solutions that help manage resistance and residues without compromising performance, and Mevalone Delta's broad label and short pre-harvest interval make it a valuable tool for them. We look forward to building on our successful partnership with Eden.”

 

For further information contact:

 

Eden BioSolutions plc

www.edenresearch.com

Sean Smith, Chief Executive Officer

Via Walbrook PR

Alex Abrey, Chief Financial Officer

 

 

 

Cavendish Capital Markets Limited (Nominated advisor and joint broker)

Tel: 020 7220 0500

Giles Balleny / Elysia Bough (Corporate Finance)

 

Harriet Ward (Corporate Broking) / Dale Bellis (Sales)

 

 

 

Oberon Capital (Joint Broker)

Tel: 020 3179 5300

Mike Seabrook / Aimee McCusker

 

 

 

Walbrook PR (Media Relations & Investor Relations)

Tel: 020 7933 8780 or eden@walbrookpr.com

Paul McManus / Nick Rome

/ Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7748 325 236

/ Mob: +44 7876 741 001

 

 


 

Notes to Editors:

 

Eden BioSolutions is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which targets fungal diseases, such as Botrytis cinerea, powdery mildew, and downy mildew, affecting high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally. Mevalone Delta is a new, enhanced version of Mevalone®.

 

Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which the Company still holds to date. The Green Economy Mark recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenbiosolutions.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLBDBSGBDGLD
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Eden Research CEO talks revenue growth and latest Ecovelex regulatory win

Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive's Stephen Gunnion about recent developments, including the company's growth and new regulatory achievements. Smith highlighted the second consecutive approval for Ecovelex in Italy, an important product in their...

on 11/08/2024

8 min read